Biotech company BioSenic (Euronext Brussels:BIOS) (Euronext Paris:BIOS) announced on Tuesday that it has been granted a key new patent by the European Patent Office for its new composite formulation of anti-inflammatory compounds that lowers the dosage of arsenic trioxide (ATO) by combining it with copper salts.

Entitled 'Use of metal ions to potentiate the therapeutic effects of arsenic' (EP3972613), the patent covers the therapeutic use of the new formulation with potential applications in cancer, infectious and immune diseases. The formulation has the potential for administration through intravenous, oral and other novel routes. BioSenic plans to conduct international clinical trials in diseases with unmet medical needs to support market access approvals.

François Rieger, chairman and CEO of BioSenic, stated that this patent opens new avenues for treating diseases with clinical unmet medical needs in the field of immunity and in oncology, where ATO has already demonstrated results for patients with acute promyelocytic leukemia.

BioSenic has generated promising results from the combination of ATO and copper salts in preclinical models of autoimmune diseases such as chronic graft versus host disease and systemic sclerosis, providing data to support the potential of the combination therapy for clinical trials.